Filing Details

Accession Number:
0001144204-17-013027
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-06 17:48:35
Reporting Period:
2017-03-02
Filing Date:
2017-03-06
Accepted Time:
2017-03-06 17:48:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609351 Spark Therapeutics Inc. ONCE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1590102 Anand Mehra Sofinnova Ventures,
3000 Sand Hill Road, 4-250
Menlo Park CA 94025
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-03-02 15,275 $65.01 699,430 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Venture Partners VIII, L.P. ("SVP VIII") on December 23, 2016.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.06, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  3. The securities are owned directly by SVP VIII. Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.